Author

Anjali Nandal

National Institutes of Health

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:genetic perturbation / CRISPR· 1 Organism:mouse· 1

Frequent Co-Authors

Arati RaziuddiniD· 1 shared Austin T.K. HokeiD· 1 shared Charalampos S. FloudasiD· 1 shared Christine N. MilleriD· 1 shared Elijah F. EdmondsoniD· 1 shared Farhoud FarajiiD· 1 shared Federico ComoglioiD· 1 shared Gary L. GalliaiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Arati RaziuddinORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

In vivo CRISPR screening identifies NF1/RASA1/TP53 co-mutations and downstream MEK signaling as a common key mechanism of sinonasal tumorigenesis

Kenny Vu, Sreenivasulu Gunti, Ramya Viswanathan, Anjali Nandal, Riley M. Larkin, Sung‐Woo Cho, Jonathan Zou, Shivani Ramolia, Austin T.K. Hoke, Siani Barbosa, Gary L. Gallia, Lisa M. Rooper, Charalampos S. Floudas, Hui Wen Cheng, Christine N. Miller, , Nyall R. London

This study identifies NF1/RASA1/TP53 co-mutations and MEK signaling as key drivers of sinonasal tumorigenesis through in vivo CRISPR screening and drug response testing.

bioRxiv · May 19, 2025 · PreprintCancer Biology